Accessibility Menu
Decoy Therapeutics logo

Decoy Therapeutics(NASDAQ) DCOY

Current Price$5.05
Market Cap$2.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year-96%
1 Month-21%
Decoy Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.952026-07-22
Decoy Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-19.9%USD 6.182026-07-15
1 month-21.43%USD 6.302026-06-22
3 month-8.67%USD 5.422026-04-23
Year to date-36.42%USD 7.792025-12-31
1 year-96.13%USD 127.842025-07-22
3 year-99.67%USD 1,512.002023-07-21
5 year-99.98%USD 31,086.002021-07-23
Since inception-100%USD 424,799.662019-07-22

Decoy Therapeutics Financials at a Glance

Market Cap

$2.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$13.03M

EPS (TTM)

-$124.04

P/E Ratio

-0.04

Dividend

$0.00

Beta (Volatility)

0.45 (Low)

Price

$5.05

Volume

41

Open

$5.00

Previous Close

$4.95

Daily Range

$4.90 - $5.36

52-Week Range

$4.32 - $415.80

Estimated Earnings Date

Aug 11, 2026

DCOY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Decoy Therapeutics

Decoy Therapeutics develops new medicines for serious diseases. Its main focus is on drugs for infections and cancer. The company uses artificial intelligence to design these medicines faster for patients with high medical needs.

Peptides, Platforms, and Possibilities: What Decoy Sells

  • Peptide Conjugate Therapeutics: Experimental drugs designed to target viruses and cancer, aimed at patients with limited treatment options. (0% of revenue; pre-commercial)
  • IMP3ACT Platform: Technology that uses artificial intelligence and fast chemistry to create new drug candidates quickly. (0% of revenue; supports all R&D)
  • D-MAVs (Multi-Antivirals): Peptide-based drugs targeting multiple viruses, including a nasal spray for coronavirus prevention. (0% of revenue; preclinical)
  • Legacy Small Molecule Drugs: Older drug candidates for cancer, now being adapted into new peptide-based formats. (0% of revenue; pre-commercial)

Growth Spurts and Strategic Moves

  • Completed merger with Legacy Decoy in November 2025, adding new drug assets.
  • Raised $6.3 million in a public offering in November 2025.
  • Secured non-dilutive funding from Gates Foundation, BARDA, and Johnson & Johnson since 2023.
  • Expanded manufacturing partnerships with contract organizations in 2025.

Why Decoy Is a Bit Different

Decoy uses artificial intelligence to speed up drug design and manufacturing. Its platform focuses on making drugs that can target several diseases at once. The company aims to respond quickly to new health threats using adaptable technology.

Five Things You Need to Know

  • No product sales revenue in 2023, 2024, or 2025.
  • Net loss was $895,130 in QQ3 2025, improved 11.1% from QQ3 2024.
  • Cash, cash equivalents, and restricted cash totaled $10.7 million at December 31, 2025.
  • Operating expenses reached $12.6 million in 2025, up from $5.7 million in 2024.
  • Company relies on grants and equity funding to support operations.

Bottom Line

Decoy Therapeutics is an early-stage biotech using artificial intelligence to develop new drugs. The company remains pre-commercial, with ongoing research and a focus on high-need patient groups.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

11

CEO

Frederick E. Pierce, II

Website

decoytx.com

Headquarters

Houston, TX 77021, US

DCOY Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-395.42%

Return on Capital

-214.20%

Return on Assets

-154.73%

Earnings Yield

-25.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

532.00K

Volume

41

Avg. Volume

229.26K

Financials (TTM)

Gross Profit

-$8.52M

Operating Income

-$13.18M

EBITDA

-$13.02M

Operating Cash Flow

-$6.53M

Capital Expenditure

$4.00

Free Cash Flow

-$6.53M

Cash & ST Invst.

$7.82M

Total Debt

$0.00

Decoy Therapeutics Performance Analysis

Decoy Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Decoy Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Decoy Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -21,423.9792.8%
20232023-12-31USD -5,532.49-74.2%
20242024-12-31USD -1,043.06-81.1%
20252025-12-31USD -129.10-87.6%
Decoy Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3056.1%
Q32025-09-3073.2%
Q42025-12-31-927.7%
Q12026-03-3177.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$239.38K

N/A

Employees

11

N/A

Net Income

-$2.22M

-30.1%

EBITDA

-$2.22M

-29.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$7.82M

+334.9%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.55%

N/A

Return on Invested Capital

-3.40%

N/A

Free Cash Flow

-$2.89M

-144.5%

Operating Cash Flow

-$2.89M

-144.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GTBPGT Biopharma, Inc.
$0.35-3.54%
SLXNSilexion Therapeutics Ltd.
$2.52+0.40%
ATXIAvenue Therapeutics, Inc.
$0.27+3.85%
ENVBEnveric Biosciences, Inc.
$1.34+1.52%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$212.25+0.02%
NOKNokia
$10.30-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
TAT&T
$23.04+0.03%

Questions About DCOY

What is the current price of Decoy Therapeutics?

Decoy Therapeutics is trading at $4.95 per share.

What is the 52-week range for Decoy Therapeutics?

Over the past 52 weeks, Decoy Therapeutics has traded between $4.32 and $415.80.

How much debt does Decoy Therapeutics have?

As of the most recent reporting period, Decoy Therapeutics reported total debt of $0.00.

How much cash does Decoy Therapeutics have on hand?

Decoy Therapeutics reported $7.82M in cash and cash equivalents in its most recent financial results.

What is Decoy Therapeutics’s dividend yield?

Decoy Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services